Q3 2025 AxoGen Inc Earnings Call Transcript
Key Points
- Axogen Inc (AXGN) reported strong revenue growth of 23.5% in Q3 2025 compared to the same period last year, reaching $60.1 million.
- The company achieved a gross margin of 76.6%, an increase from 74.9% in the same period last year, driven by lower inventory write-offs and reduced shipping costs.
- Axogen Inc (AXGN) successfully ended its case stock sales program, transitioning customers to direct sales, which positively impacted Q3 revenue by $1.6 million.
- The company expanded its commercial infrastructure, meeting its goal to double the breast sales force by the end of 2025.
- Axogen Inc (AXGN) received significant validation from medical societies, with endorsements recognizing nerve allograft as a standard medical practice option for peripheral nerve defects.
- Revenue growth from high potential accounts was slightly below target, with 64% of revenue growth driven by these accounts, compared to the goal of 66%.
- The discontinuation of the case stock program reduced revenue growth from high potential accounts by an estimated 4%.
- Operating expenses increased to $44.1 million, up from $36.8 million in the third quarter of 2024.
- The FDA extended the PDUFA goal date for the biologics license application for Avance Nerve Graft to December 5, 2025, due to a major amendment.
- Gross margin for the first three quarters of 2025 decreased by 1.3% compared to the same period in 2024, due to increased product costs.
Good morning. Joining me on today's call is Michael Dale, AxoGen 's Chief Executive Officer and Board Director and Lindsey Hartley, Chief Financial Officer. Michael will discuss 3rd Quarter of 2025 financial results and corporate highlights. Lindsay will then provide details on financial performance, guidance, and overall outlook for the year. This will be followed by a question-and-answer session. Today's call and presentation is being webcast live via webcast which is available on the investors section of Axoen's website. Following the end of the live call, a replay will be available in the investors section of the company's website at www.AxoGeninc.com.
Before we get started, I'd like to remind you that during the conference call, the company will make projections and forward-looking statements. Forward-looking statements include but are not limited to statements relating to financial guidance, market development priorities, estimated market opportunities, timing for future product and application launches. And the company's
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
